Edition:
United States

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

17.40USD
24 Mar 2017
Change (% chg)

$-0.49 (-2.71%)
Prev Close
$17.88
Open
$17.76
Day's High
$18.03
Day's Low
$17.31
Volume
69,654
Avg. Vol
76,762
52-wk High
$19.10
52-wk Low
$7.14

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals qtrly loss per share $ 0.54
Monday, 6 Mar 2017 07:15am EST 

Concert Pharmaceuticals Inc : Concert pharmaceuticals reports year ended 2016 financial results . Concert pharmaceuticals inc - ctp-543 on track to advance into phase 2a trial . Qtrly loss per share $ 0.54 . Concert pharmaceuticals- expects cash, cash equivalents and investments as of december 31, 2016, to be sufficient to fund company through q2 of 2018 .Concert pharmaceuticals inc - upon closing of ctp-656 asset purchase agreement, pro forma cash is expected to be sufficient to fund company into 2021.  Full Article

Vertex to acquire CTP-656 from Concert Pharmaceuticals
Monday, 6 Mar 2017 07:00am EST 

Vertex Pharmaceuticals Inc : Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis . Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments . Vertex Pharmaceuticals Inc- signed a definitive asset purchase agreement to acquire CTP-656 from concert pharmaceuticals . Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating underlying cause of CF . Vertex Pharmaceuticals Inc - Vertex will pay concert $160 million in cash for all worldwide development and commercialization rights to CTP-656 .Vertex Pharmaceuticals - Concert's board of directors unanimously supports transaction and recommends that concert's shareholders vote in favor of it.  Full Article

Concert pharmaceuticals provides further details on CTP-656 development in U.S. and Europe
Tuesday, 17 Jan 2017 07:00am EST 

Concert Pharmaceuticals Inc : Concert Pharmaceuticals provides further details on CTP-656 development in U.S. and Europe . Concert Pharma - FDA informed co that in order to support dose selection for phase 3, adequate washout period required in addition to placebo-control . Intends to further discuss additional feedback with FDA . Topline data for ongoing phase 2 trial for CTP-656 in U.S. Expected by year-end 2017 .Topline data from european phase 2 study of CTP-656 is expected by year-end 2017.  Full Article

Concert Pharmaceuticals Inc says topline results of phase 2 trial of CTP-656 are expected by year-end 2017
Wednesday, 21 Dec 2016 07:30am EST 

Concert Pharmaceuticals Inc : Concert Pharmaceuticals Inc says topline results of phase 2 trial of CTP-656 are expected by year-end 2017 .Concert Pharmaceuticals initiates phase 2 clinical trial evaluating CTP-656 for the treatment of cystic fibrosis.  Full Article

Concert Pharmaceuticals announces CTP-543 positive top-line phase 1 results
Wednesday, 14 Dec 2016 07:30am EST 

Concert Pharmaceuticals Inc : Concert pharmaceuticals - phase 2A trial expected to commence in Q1 next year and topline primary outcome data expected by end of 2017 . Concert pharmaceuticals announces CTP-543 positive top-line phase 1 results . Concert Pharmaceuticals Inc says Phase 2a clinical trial for CTP-543 is expected to begin in Q1 of 2017 . Concert pharmaceuticals - CTP-543 well-tolerated across all dose groups in study & there were no serious adverse events in subjects who received CTP-543 . Concert pharmaceuticals inc - intends to present phase 1 findings at a medical conference in 2017 .Concert pharmaceuticals-phase 2 a trial for CTP-543 is expected to commence in Q1 of next year, topline primary outcome data is expected by end of 2017.  Full Article

Concert Pharmaceuticals Q2 loss per share $0.60
Tuesday, 9 Aug 2016 07:00am EDT 

Concert Pharmaceuticals Inc : Concert Pharmaceuticals reports second quarter 2016 financial results and provides company update . Q2 loss per share $0.60 .Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.  Full Article

Concert Pharma initiates phase 1 trial of CTP-543
Thursday, 19 May 2016 07:00am EDT 

Concert Pharmaceuticals : Expects to report top-line data upon completion of multiple-dose phase 1 program in q4 of 2016 . Expects to initiate a phase 2 efficacy study in early 2017 .Initiates Phase 1 Trial Of Ctp-543 as a new treatment for alopecia areata.  Full Article

Concert Pharmaceuticals, Inc announces positive data from multiple dose phase 1 Clinical Trial of CTP-656
Thursday, 28 Apr 2016 04:02pm EDT 

Concert Pharmaceuticals, Inc:Positive topline data from a Phase 1 multiple ascending dose clinical trial of CTP-656.CTP-656 is a novel deuterium-modified version of ivacaftor. Ivacaftor is commercially available under the name Kalydeco(reg).Results of the Phase 1 trial also showed that CTP-656 was well-tolerated and its safety profile was comparable to that of Kalydeco.Company expects to present the Phase 1 multiple ascending dose results at the 39(th)European Cystic Fibrosis Conference being held June 8-11, 2016 in Basel, Switzerland.  Full Article

Concert Pharmaceuticals Inc gives FY 2015 earnings guidance
Thursday, 5 Nov 2015 07:00am EST 

Concert Pharmaceuticals Inc:Expects to be profitable for FY 2015.  Full Article

Concert Pharmaceuticals announces results of phase 1 trial that demonstrates CTP-656
Tuesday, 22 Sep 2015 11:00am EDT 

Concert Pharmaceuticals Inc:Announced positive data from a Phase 1 single ascending dose clinical trial of CTP-656.Says results trial showed that CTP-656 was well-tolerated and its safety profile was comparable to Kalydeco.Favorable safety and pharmacokinetic profile of CTP-656 observed in single ascending dose trial.Says expects to report top-line results from this multiple ascending dose phase 1 trial in the first half of 2016.Says there were no serious adverse events reported in subjects who received CTP-656.  Full Article

More From Around the Web